{"id":78722,"topic":"peptides","source":"The Manila Times","title":"First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA - The Manila Times","url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","url_hash":"870989ff62509fd2b2c866b1e34ceac7e7792b68","author":"","summary":"<a href=\"https://news.google.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?oc=5\" target=\"_blank\">First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Manila Times</font>","content":null,"image_url":null,"lang":"en","published_at":"2026-09-09T13:16:53+00:00","fetched_at":"2026-09-09T14:15:09+00:00","status":"read","starred":0,"extract_state":"failed","summary_auto":null,"cluster_id":null,"extract_retries":2,"extract_error":"http_403","contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":1056,"usable_text_length":1056,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":1056}},"news_item":{"id":78722,"canonical_url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","source_url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","title":"First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA - The Manila Times","source_name":"The Manila Times","author":null,"published_at":"2026-09-09T13:16:53+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.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?oc=5\" target=\"_blank\">First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Manila Times</font>","full_text":null,"excerpt":"<a href=\"https://news.google.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?oc=5\" target=\"_blank\">First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Manila Times</font>","extraction":{"state":"failed","confidence":0.0,"error":"http_403","explanation":"Low confidence: HTTP extraction failure (http_403).","diagnostics_url":"/api/diagnose?url=https%3A//www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":1056,"usable_text_length":1056,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":1056}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA - The Manila Times","url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","summary":"<a href=\"https://news.google.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?oc=5\" target=\"_blank\">First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Manila Times</font>","source":"The Manila Times","date":"2026-09-09T13:16:53+00:00","content":"","confidence":0.0,"diagnostics_url":"/api/diagnose?url=https%3A//www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","quality_bucket":"failed","failure_kind":"http","retryable":false,"quality_reason":"Low confidence: HTTP extraction failure (http_403).","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":1056,"usable_text_length":1056,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":1056}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/78722","export_markdown":"/api/items/78722/export?format=markdown","export_json":"/api/items/78722/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699"},"formats":{"full":{"id":78722,"title":"First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA - The Manila Times","url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","source":"The Manila Times","author":null,"published_at":"2026-09-09T13:16:53+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"<a href=\"https://news.google.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?oc=5\" target=\"_blank\">First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Manila Times</font>","full_text":null,"reading_time_min":1,"extraction":{"state":"failed","confidence":0.0,"error":"http_403","explanation":"Low confidence: HTTP extraction failure (http_403).","diagnostics_url":"/api/diagnose?url=https%3A//www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":1056,"usable_text_length":1056,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":1056}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":1056,"usable_text_length":1056,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":1056}},"actions":{"read":"/item/78722","export_markdown":"/api/items/78722/export?format=markdown","export_json":"/api/items/78722/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699"}},"digest":{"id":78722,"title":"First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA - The Manila Times","url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","source":"The Manila Times","topic":"peptides","published_at":"2026-09-09T13:16:53+00:00","excerpt":"<a…","quality_bucket":"failed","quality_reason":"Low confidence: HTTP extraction failure (http_403).","reading_time_min":1,"cluster_id":null},"card":{"display_title":"First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA - The Manila Times","subtitle":"The Manila Times · 2026-09-09","summary":"<a…","badges":["quality:failed","issue:http"],"links":{"read":"/item/78722","original":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","diagnose":"/api/diagnose?url=https%3A//www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699"},"quality_warning":"Low confidence: HTTP extraction failure (http_403)."},"export":{"title":"First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA - The Manila Times","url":"https://www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","summary":"<a href=\"https://news.google.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?oc=5\" target=\"_blank\">First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Manila Times</font>","source":"The Manila Times","date":"2026-09-09T13:16:53+00:00","content":"","confidence":0.0,"diagnostics_url":"/api/diagnose?url=https%3A//www.manilatimes.net/2026/09/09/tmt-newswire/pr-newswire/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acting-once-weekly-oral-peptide-glp-1-ra/2421699","quality_bucket":"failed","failure_kind":"http","retryable":false,"quality_reason":"Low confidence: HTTP extraction failure (http_403).","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":1056,"usable_text_length":1056,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":1056}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}